Advertisement
Loading...

Carlsmed, Inc.

CARLNASDAQ
Healthcare
Medical - Healthcare Information Services
$11.01
$0.25(2.32%)
U.S. Market opens in 61h 29m

Carlsmed, Inc. Fundamental Analysis

Carlsmed, Inc. (CARL) shows moderate financial fundamentals with a PE ratio of -8.90, profit margin of -58.80%, and ROE of -61.82%. The company generates $0.1B in annual revenue with strong year-over-year growth of 85.94%.

Key Strengths

Cash Position32.84%
PEG Ratio-0.24
Current Ratio11.88

Areas of Concern

ROE-61.82%
Operating Margin-38.59%
We analyze CARL's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -59.7/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-59.7/100

We analyze CARL's fundamental strength across five key dimensions:

Efficiency Score

Weak

CARL struggles to generate sufficient returns from assets.

ROA > 10%
-27.94%

Valuation Score

Excellent

CARL trades at attractive valuation levels.

PE < 25
-8.90
PEG Ratio < 2
-0.24

Growth Score

Moderate

CARL shows steady but slowing expansion.

Revenue Growth > 5%
85.94%
EPS Growth > 10%
-41.33%

Financial Health Score

Excellent

CARL maintains a strong and stable balance sheet.

Debt/Equity < 1
0.19
Current Ratio > 1
11.88

Profitability Score

Weak

CARL struggles to sustain strong margins.

ROE > 15%
-6182.47%
Net Margin ≥ 15%
-58.80%
Positive Free Cash Flow
No

Key Financial Metrics

Is CARL Expensive or Cheap?

P/E Ratio

CARL trades at -8.90 times earnings. This suggests potential undervaluation.

-8.90

PEG Ratio

When adjusting for growth, CARL's PEG of -0.24 indicates potential undervaluation.

-0.24

Price to Book

The market values Carlsmed, Inc. at 3.20 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

3.20

EV/EBITDA

Enterprise value stands at -9.38 times EBITDA. This is generally considered low.

-9.38

How Well Does CARL Make Money?

Net Profit Margin

For every $100 in sales, Carlsmed, Inc. keeps $-58.80 as profit after all expenses.

-58.80%

Operating Margin

Core operations generate -38.59 in profit for every $100 in revenue, before interest and taxes.

-38.59%

ROE

Management delivers $-61.82 in profit for every $100 of shareholder equity.

-61.82%

ROA

Carlsmed, Inc. generates $-27.94 in profit for every $100 in assets, demonstrating efficient asset deployment.

-27.94%

Following the Money - Real Cash Generation

Operating Cash Flow

Carlsmed, Inc. generates limited operating cash flow of $-34.27M, signaling weaker underlying cash strength.

$-34.27M

Free Cash Flow

Carlsmed, Inc. generates weak or negative free cash flow of $-34.76M, restricting financial flexibility.

$-34.76M

FCF Per Share

Each share generates $-1.28 in free cash annually.

$-1.28

FCF Yield

CARL converts -11.50% of its market value into free cash.

-11.50%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-8.90

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.24

vs 25 benchmark

P/B Ratio

Price to book value ratio

3.20

vs 25 benchmark

P/S Ratio

Price to sales ratio

5.30

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.19

vs 25 benchmark

Current Ratio

Current assets to current liabilities

11.88

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.62

vs 25 benchmark

ROA

Return on assets percentage

-0.28

vs 25 benchmark

ROCE

Return on capital employed

-0.20

vs 25 benchmark

How CARL Stacks Against Its Sector Peers

MetricCARL ValueSector AveragePerformance
P/E Ratio-8.9028.62 Better (Cheaper)
ROE-61.82%783.00% Weak
Net Margin-58.80%-44009.00% (disorted) Weak
Debt/Equity0.190.39 Strong (Low Leverage)
Current Ratio11.884.12 Strong Liquidity
ROA-27.94%-21805.00% (disorted) Weak

CARL outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Carlsmed, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

14.59%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

50.02%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

48.18%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ